Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hillel Galitzer

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Opinion in Nephrology and Hypertension|July 29, 2008
Fibroblast growth factor 23 acts on the parathyroid to decrease parathyroid hormone secretionHillel Galitzer, Iddo Ben-Dov, Vardit Lavi-Moshayoff, et al.
BMC Biology|April 29, 2009
The calcium-sensing receptor regulates parathyroid hormone gene expression in transfected HEK293 cellsHillel Galitzer, Vardit Lavi-Moshayoff, Morris Nechama, et al.
International Journal of Pharmaceutics: X|October 27, 2021
The combined effect of permeation enhancement and proteolysis inhibition on the systemic exposure of orally administrated peptides: Salcaprozate sodium, soybean trypsin inhibitor, and teriparatide study in pigsGregory Burshtein, Constantin Itin, Jonathan C Y Tang, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 9, 2006
Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic ratsIddo Z Ben-Dov, Orit Pappo, Miri Sklair-Levy, et al.
The Journal of Clinical Investigation|November 10, 2007
The parathyroid is a target organ for FGF23 in ratsIddo Z Ben-Dov, Hillel Galitzer, Vardit Lavi-Moshayoff, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 5, 2024
Oral daily PTH(1-34) tablets (EB613) in postmenopausal women with low BMD or osteoporosis: a randomized, placebo-controlled, 6-month, phase 2 studyLiana Tripto-Shkolnik, Auryan Szalat, Gloria Tsvetov, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 5, 2021
Safety and Efficacy of Oral Human Parathyroid Hormone (1-34) in Hypoparathyroidism: An Open-Label StudySofia Ish-Shalom, Yoseph Caraco, Nariman Saba Khazen, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Opinion in Nephrology and Hypertension|July 29, 2008
Fibroblast growth factor 23 acts on the parathyroid to decrease parathyroid hormone secretionHillel Galitzer, Iddo Ben-Dov, Vardit Lavi-Moshayoff, et al.
BMC Biology|April 29, 2009
The calcium-sensing receptor regulates parathyroid hormone gene expression in transfected HEK293 cellsHillel Galitzer, Vardit Lavi-Moshayoff, Morris Nechama, et al.
International Journal of Pharmaceutics: X|October 27, 2021
The combined effect of permeation enhancement and proteolysis inhibition on the systemic exposure of orally administrated peptides: Salcaprozate sodium, soybean trypsin inhibitor, and teriparatide study in pigsGregory Burshtein, Constantin Itin, Jonathan C Y Tang, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 9, 2006
Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic ratsIddo Z Ben-Dov, Orit Pappo, Miri Sklair-Levy, et al.
The Journal of Clinical Investigation|November 10, 2007
The parathyroid is a target organ for FGF23 in ratsIddo Z Ben-Dov, Hillel Galitzer, Vardit Lavi-Moshayoff, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 5, 2024
Oral daily PTH(1-34) tablets (EB613) in postmenopausal women with low BMD or osteoporosis: a randomized, placebo-controlled, 6-month, phase 2 studyLiana Tripto-Shkolnik, Auryan Szalat, Gloria Tsvetov, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 5, 2021
Safety and Efficacy of Oral Human Parathyroid Hormone (1-34) in Hypoparathyroidism: An Open-Label StudySofia Ish-Shalom, Yoseph Caraco, Nariman Saba Khazen, et al.
Pageof 1